Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 918 active trials
347 drugs · 19,206 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 16 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Therapeutic Tumor Infiltrating Lymphocytes | Phase 2 | Phase 2 | 16 | 11 | 0 | 50 | 0 | — | — | 1993-07 |
| Adavosertib | Phase 2 | Phase 2 | 12 | 1 | 0 | 47 | 0 | — | — | Feb 25, 2008 |
| Berzosertib | Phase 2 | Phase 2 | 12 | 0 | 0 | 21 | 0 | — | — | Dec 10, 2012 |
| Sapanisertib | Phase 2 | Phase 2 | 10 | 3 | 0 | 45 | 0 | — | — | Jan 4, 2010 |
| KRAS G12D Inhibitor HRS-4642 | Phase 2 | Phase 2 | 7 | 4 | 0 | 7 | 0 | — | — | Sep 21, 2022 |
| Vistusertib | Phase 2 | Phase 2 | 6 | 1 | 0 | 29 | 0 | — | — | 2009-12 |
| Elimusertib | Phase 2 | Phase 2 | 6 | 0 | 0 | 10 | 0 | — | — | Jul 6, 2017 |
| Camonsertib | Phase 2 | Phase 2 | 5 | 3 | 0 | 8 | 0 | — | — | Dec 27, 2017 |
| Pidnarulex | Phase 2 | Phase 2 | 5 | 5 | 0 | 7 | 0 | — | — | Jun 13, 2016 |
| Platinum Doublet | Phase 2 | Phase 2 | 5 | 2 | 0 | 5 | 0 | — | — | Jul 16, 2019 |
| Belvarafenib | Phase 2 | Phase 2 | 4 | 2 | 0 | 6 | 0 | — | — | Jan 12, 2015 |
| Anvumetostat | Phase 2 | Phase 2 | 4 | 0 | 0 | 5 | 0 | — | — | Feb 1, 2022 |
| Avutometinib And Defactinib | Phase 2 | Phase 2 | 4 | 1 | 0 | 5 | 0 | — | — | Dec 21, 2020 |
| L19IL2 | Phase 2 | Phase 2 | 4 | 3 | 0 | 5 | 0 | — | — | 2005-11 |
| Samotolisib | Phase 2 | Phase 2 | 3 | 1 | 0 | 13 | 0 | — | — | Jul 31, 2012 |
| Lunresertib | Phase 2 | Phase 2 | 3 | 2 | 0 | 4 | 0 | — | — | Apr 30, 2021 |
| Anti-PD-L1 Monoclonal Antibody | Phase 2 | Phase 2 | 3 | 3 | 0 | 3 | 0 | — | — | 2023-08 |
| Rezatapopt | Phase 2 | Phase 2 | 3 | 3 | 0 | 3 | 0 | — | — | Oct 29, 2020 |
| Prexasertib | Phase 2 | Phase 2 | 2 | 2 | 0 | 19 | 0 | — | — | 2010-02 |
| Mocetinostat | Phase 2 | Phase 2 | 2 | 0 | 0 | 18 | 0 | — | — | 2004-04 |
| Quisinostat | Phase 2 | Phase 2 | 2 | 1 | 0 | 7 | 0 | — | — | 2007-08 |
| FACT Complex-targeting Curaxin CBL0137 | Phase 2 | Phase 2 | 2 | 2 | 0 | 5 | 0 | — | — | 2013-07 |
| PD1 Inhibitor | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | Apr 26, 2021 |
| PD-L1 Inhibitor | Phase 2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | 2022-04 |
| Pertuzumab/Trastuzumab Regimen | Phase 2 | Phase 2 | 2 | 1 | 0 | 4 | 0 | — | — | Mar 1, 2010 |
| Carboplatin/Pemetrexed Regimen | Phase 2 | Phase 2 | 2 | 2 | 0 | 3 | 0 | — | — | Oct 12, 2017 |
| Fasudil | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Aug 1, 2024 |
| Platinum Compound | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Jul 16, 2019 |
| WRN Inhibitor RO7589831 | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Jan 25, 2024 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 1 | 0 | 0 | 45 | 0 | — | — | Apr 15, 2008 |
| Cixutumumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 43 | 0 | — | — | 2005-10 |
| Uprosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 11 | 0 | — | — | Jun 16, 2009 |
| FOLFOX-6 Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 9 | 0 | — | — | 2008-09 |
| Letetresgene Autoleucel | Phase 2 | Phase 2 | 1 | 0 | 0 | 7 | 0 | — | — | Feb 1, 2016 |
| Fadraciclib | Phase 2 | Phase 2 | 1 | 1 | 0 | 6 | 0 | — | — | Sep 28, 2015 |
| Therapeutic Glucocorticoid | Phase 2 | Phase 2 | 1 | 0 | 0 | 6 | 0 | — | — | 2006-11 |
| Vociprotafib | Phase 2 | Phase 2 | 1 | 0 | 0 | 6 | 0 | — | — | Sep 28, 2018 |
| Afimoxifene | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2003-04 |
| Anti-EGFR Monoclonal Antibody | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | Jan 1, 2016 |
| Izorlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2010-08 |
| Derazantinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Sep 28, 2017 |
| MEK Inhibitor REC-4881 | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2009-12 |
| Zenocutuzumab-zbco | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | 2015-01 |
| Lasofoxifene | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Mar 1, 2010 |
| Tranilast | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Jul 20, 2022 |
| Anti-VEGF Monoclonal Antibody | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 1, 2027 |
| BCR-ABL Inhibitor HS-10382 | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 26, 2024 |
| CTLA-4 Inhibitor | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 14, 2026 |
| CTX-712 | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 25, 2023 |
| Larotrectinib Regimen | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 14, 2024 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.